Recently, the feasibility of treating genetic diseases caused by single-gene mutations was established in a Phase 1 trial for transthyretin amyloidosis, a disease caused by the accumulation of misfolded transthyretin (TTR) [11]. Here, TTR is linked to amyloidosis.